Sobi's Participation in the ASH Annual Meeting
Sobi® has announced its active participation in the ASH 2025 Annual Meeting, set to be held from December 6 to 9. At this prestigious event, Sobi aims to underscore its dedication to enhancing patient care in the field of haematology. This year, Sobi will present 19 scientific abstracts, including two key oral presentations. These abstracts will highlight cutting-edge clinical studies and innovative treatment options available through Sobi's portfolio, which features treatments such as efanesoctocog alfa, pegcetacoplan, avatrombopag, emapalumab, and pacritinib.
Key Highlights from Sobi's Research
Dr. Lydia Abad-Franch, Head of R&D and Medical Affairs, expressed the significance of the findings being presented at ASH. Among the highlights, Sobi will reveal a detailed post hoc analysis demonstrating that pacritinib not only stabilizes but can also reduce spleen size while improving haematologic parameters for patients suffering from high-risk myelofibrosis. This critical research aims to address vital issues that significantly affect patients’ daily lives and overall quality of life.
Focusing on Specific Treatment Modalities
Sobi will provide in-depth discussions surrounding several of its treatment innovations:
- Improving outcomes in patients with Paroxysmal Nocturnal Haemoglobinuria (PNH) using complement inhibitors.
- Insights from the user's experience with pegcetacoplan and its on-body injector for treating PNH.
A Closer Look at Efanesoctocog Alfa
One of Sobi's cornerstone medications, ALTUVOCT® (efanesoctocog alfa), will be featured prominently at ASH. This product is designed for both treatment and preventive care of bleeding in patients with haemophilia A. The presentations will showcase critical data indicating improvements in clinical outcomes, tailored for diverse patient demographics.
Key Oral and Poster Presentations
Some significant oral and poster presentations to look out for include:
- A clinical outcomes analysis on Efanesoctocog Alfa with up to four years of data.
- Real-world treatment experience and results from Avatrombopag in patients transitioning from other therapies.
Collaborative Efforts and Future Developments
Sobi collaborates closely with both Sanofi and Apellis to enhance the development and commercialization of their flagship products. Their joint efforts are aimed at optimizing treatment strategies for rare blood disorders, ensuring patients have access to the latest therapies.
Sobi is also looking forward to continuous advancements in treatments for conditions like primary immune complex membranoproliferative glomerulonephritis, showcasing the broad impact of their investigational studies.
Looking Ahead to the ASH Meeting
The ASH 2025 Meeting is not just a platform for showcasing Sobi's innovations; it also serves as a valuable opportunity for learning, collaboration, and dialogue among leading experts in hematology. With their robust pipeline and commitment to patient care, Sobi continues to exemplify leadership in biopharma.
About Sobi
Sobi is a global biopharmaceutical company dedicated to unlocking the potential of breakthrough innovations that transform the lives of individuals with rare diseases. With a workforce of around 1,900, Sobi operates across multiple regions including Europe, North America, and Asia, consistently striving to provide novel therapeutic solutions.
Frequently Asked Questions
What is Sobi presenting at the ASH 2025 Annual Meeting?
Sobi will present 19 scientific abstracts highlighting advancements in treatments, including pacritinib and efanesoctocog alfa.
Who is leading the Sobi presentations at ASH?
Dr. Lydia Abad-Franch, the Head of R&D and Medical Affairs at Sobi, is responsible for leading discussions on key findings.
What are some specific drugs highlighted in Sobi's studies?
Dealing with haemophilia and blood disorders, Sobi's presentations will feature efanesoctocog alfa, pegcetacoplan, and pacritinib.
How does Sobi's research impact patient care?
The findings will potentially improve treatment outcomes for patients with rare and severe blood disorders, enhancing quality of life.
What collaborations does Sobi have?
Sobi collaborates with Sanofi and Apellis for the development and commercialization of key products targeting rare blood disorders.
